Per Kongsted

800 total citations
21 papers, 595 citations indexed

About

Per Kongsted is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Per Kongsted has authored 21 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Per Kongsted's work include Prostate Cancer Treatment and Research (9 papers), CAR-T cell therapy research (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Per Kongsted is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), CAR-T cell therapy research (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Per Kongsted collaborates with scholars based in Denmark, Sweden and United States. Per Kongsted's co-authors include Per thor Straten, Lisa Sengeløv, Inge Marie Svane, Özcan Met, Troels Holz Borch, Rikke Andersen, Tania Køllgaard, Manja Idorn, Trine Zeeberg Iversen and Eva Ellebæk and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Per Kongsted

17 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Per Kongsted Denmark	8	462	427	114	93	55	21	595
Alison M. McDonnell Australia	16	432 0.9×	415 1.0×	85 0.7×	130 1.4×	25 0.5×	25	650
Arianna Draghi Denmark	12	316 0.7×	287 0.7×	111 1.0×	58 0.6×	21 0.4×	28	458
Stephanie Mittman United States	6	356 0.8×	377 0.9×	90 0.8×	49 0.5×	10 0.2×	7	516
Heather Derocher Canada	6	288 0.6×	196 0.5×	65 0.6×	32 0.3×	39 0.7×	6	406
Peggy Richard-Fiardo France	8	193 0.4×	139 0.3×	103 0.9×	38 0.4×	44 0.8×	11	340
Dimitrios Alatzoglou Switzerland	2	246 0.5×	198 0.5×	137 1.2×	31 0.3×	42 0.8×	3	409
Sreevani Arisa United States	6	206 0.4×	196 0.5×	164 1.4×	39 0.4×	40 0.7×	11	387
Lieke L. van der Woude Netherlands	6	212 0.5×	187 0.4×	77 0.7×	42 0.5×	21 0.4×	10	306
Donald Gravenor United States	9	214 0.5×	174 0.4×	150 1.3×	52 0.6×	16 0.3×	24	433
Jayashri Mahalingam Taiwan	6	313 0.7×	378 0.9×	100 0.9×	24 0.3×	19 0.3×	10	518

Countries citing papers authored by Per Kongsted

Since Specialization

Citations

This map shows the geographic impact of Per Kongsted's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Kongsted with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Kongsted more than expected).

Fields of papers citing papers by Per Kongsted

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Kongsted. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Kongsted. The network helps show where Per Kongsted may publish in the future.

Co-authorship network of co-authors of Per Kongsted

This figure shows the co-authorship network connecting the top 25 collaborators of Per Kongsted. A scholar is included among the top collaborators of Per Kongsted based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Kongsted. Per Kongsted is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pedersen, Maria, Rikke Broholm, Peter Busch Østergren, et al.. (2025). Prospective Head-to-Head Comparison of¹⁸F-PSMA PET/CT and¹⁸F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer. Journal of Nuclear Medicine. 66(2). 223–229.

Eefsen, Rikke Løvendahl, Per Kongsted, Susann Theile, et al.. (2025). CA209-8TY trial, a randomized phase 2 trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 43(16_suppl). 5018–5018.

Poulsen, Tim Svenstrup, et al.. (2024). TMPRSS2:ERGGene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer. Anticancer Research. 44(10). 4203–4211. 2 indexed citations

Borch, Troels Holz, Katja Harbst, Rikke Andersen, et al.. (2021). Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. Journal for ImmunoTherapy of Cancer. 9(7). e002703–e002703. 21 indexed citations

Levál, Amy, Henrik Kjölhede, Per Kongsted, et al.. (2018). PCN40 - A RETROSPECTIVE STUDY ON PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PRESCRIBED ABIRATERONE ACETATE + PREDNISONE PRIOR TO CHEMOTHERAPY IN SWEDEN, NORWAY AND DENMARK. Value in Health. 21. S21–S21. 1 indexed citations

Andersen, Rikke, Troels Holz Borch, Arianna Draghi, et al.. (2018). T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Annals of Oncology. 29(7). 1575–1581. 51 indexed citations

Borch, Troels Holz, Per Kongsted, Magnus Pedersen, et al.. (2018). Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients. Annals of Oncology. 29. viii402–viii402. 2 indexed citations

Kongsted, Per, Troels Holz Borch, Eva Ellebæk, et al.. (2017). Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. Cytotherapy. 19(4). 500–513. 69 indexed citations

Andersen, Rikke, Marco Donia, Eva Ellebæk, et al.. (2016). Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clinical Cancer Research. 22(15). 3734–3745. 234 indexed citations

10.

Kongsted, Per, Inge Marie Svane, Henriette Lindberg, et al.. (2016). Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer. Anti-Cancer Drugs. 27(7). 695–701. 2 indexed citations

11.

Kongsted, Per, Eva Ellebæk, Troels Holz Borch, et al.. (2016). Dendritic cell vaccination in combination with docetaxel for patients with prostate cancer – a randomized phase II study. Annals of Oncology. 27. vi371–vi371. 3 indexed citations

12.

Kongsted, Per, Inge Marie Svane, Henriette Lindberg, & Lisa Sengeløv. (2016). Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 15(2). e281–e287. 4 indexed citations

13.

Kongsted, Per, Inge Marie Svane, Henriette Lindberg, & Lisa Sengeløv. (2016). Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 14(6). e559–e568. 13 indexed citations

14.

Pedersen, Magnus, Troels Holz Borch, Morten Nielsen, et al.. (2016). T cell therapy for patients with advanced ovarian cancer: a pilot study in progress. Annals of Oncology. 27. vi375–vi375. 1 indexed citations

15.

Kongsted, Per, Inge Marie Svane, Henriette Lindberg, Gedske Daugaard, & Lisa Sengeløv. (2015). Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: Is there a clinical benefit?. Urologic Oncology Seminars and Original Investigations. 33(11). 494.e15–494.e20. 11 indexed citations

16.

Kongsted, Per, et al.. (2015). [Fatal neutropenic enterocolitis in a patient with castration-resistant prostate cancer treated with first-line chemotherapy].. PubMed. 177(2A). 24–5.

17.

Idorn, Manja, Tania Køllgaard, Per Kongsted, Lisa Sengeløv, & Per thor Straten. (2014). Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunology Immunotherapy. 63(11). 1177–1187. 149 indexed citations

18.

Larsen, Stine Kiær, Per Kongsted, Özcan Met, et al.. (2014). Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. OncoImmunology. 4(1). e968480–e968480. 25 indexed citations

19.

Andersen, Rikke, Marco Donia, Troels Holz Borch, et al.. (2014). Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma. Journal for ImmunoTherapy of Cancer. 2(S3). 6 indexed citations

20.

Andersen, Rikke, Marco Donia, Troels Holz Borch, et al.. (2014). Adoptive Cell Therapy with Tumor Infiltrating Lymphocytes and Intermediate Dose Interleukin-2 for Metastatic Melanoma. Annals of Oncology. 25. iv361–iv361. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact